Recall Weekly← all recalls
FDA-Drug2026-01-14Class IIPACKAGING DEFECT

Imprimis Tri-Moxi eye injection recalled for glass-like particles

Imprimis
GLASSNationwide distribution

Stop using Imprimis Tri-Moxi eye injections

Imprimis NJOF recalled Tri-Moxi+ eye injections because some batches contain glass-like particles. The affected batches (25JAN033A and 25JAN033B) expire in February 2026. No injuries have been reported.

  • If you have Tri-Moxi+ (NDC 71384-746-06) with lot numbers 25JAN033A or 25JAN033B, do not use it.
  • Contact your eye doctor or pharmacy immediately.
  • Ask your healthcare provider about safe alternatives for your treatment.
Hazard

Presence of particulate matter - Glass like particles.

Sold states
U.S Nationwide
Affected count
314 boxes of 6,280 pre-filled syringes
Manufactured in
1705 Route 46 Ste 6B, Ledgewood, NJ, United States
Products
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0251-2026

Don't want to check this manually?

We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Get the Sunday Brief